drugset / Trial / NCT05191628

Amniotic Membrane Visio-AMTRIX in Recurrent Macular Hole

NCT05191628 ↗

Phase 2 Terminated 12 enrolled TBF Genie Tissulaire
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this open, multicenter trial is to assess the impact of the use of an amniotic membrane graft on the closure of macular hole-associated retinal detachment in patients with failed previous macular surgery.

Timeline

Start
2020-06-10
Primary completion
2022-10-10
Completion
2022-10-10

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual rate”

Drugs

EvaluationDrugModalityDoseRoute
Subject Visio-AMTRIX Other / unclassified — Other